167 related articles for article (PubMed ID: 29975751)
1. PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
McNeill RS; Stroobant EE; Smithberger E; Canoutas DA; Butler MK; Shelton AK; Patel SD; Limas JC; Skinner KR; Bash RE; Schmid RS; Miller CR
PLoS One; 2018; 13(7):e0200014. PubMed ID: 29975751
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Liu S; Tang Y; Yan M; Jiang W
Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
[TBL] [Abstract][Full Text] [Related]
4. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
[TBL] [Abstract][Full Text] [Related]
5. Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Vitucci M; Karpinich NO; Bash RE; Werneke AM; Schmid RS; White KK; McNeill RS; Huff B; Wang S; Van Dyke T; Miller CR
Neuro Oncol; 2013 Oct; 15(10):1317-29. PubMed ID: 23814263
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations of PIK3R1 promote gliomagenesis.
Quayle SN; Lee JY; Cheung LW; Ding L; Wiedemeyer R; Dewan RW; Huang-Hobbs E; Zhuang L; Wilson RK; Ligon KL; Mills GB; Cantley LC; Chin L
PLoS One; 2012; 7(11):e49466. PubMed ID: 23166678
[TBL] [Abstract][Full Text] [Related]
8. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
[TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Madsen RR; Vanhaesebroeck B; Semple RK
Trends Mol Med; 2018 Oct; 24(10):856-870. PubMed ID: 30197175
[TBL] [Abstract][Full Text] [Related]
10. PIK3CB/p110β is a selective survival factor for glioblastoma.
Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
[TBL] [Abstract][Full Text] [Related]
11. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma.
Ross RL; McPherson HR; Kettlewell L; Shnyder SD; Hurst CD; Alder O; Knowles MA
BMC Cancer; 2016 Jul; 16():553. PubMed ID: 27465249
[TBL] [Abstract][Full Text] [Related]
13. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
[TBL] [Abstract][Full Text] [Related]
15. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
[TBL] [Abstract][Full Text] [Related]
17. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
[TBL] [Abstract][Full Text] [Related]
18. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
[TBL] [Abstract][Full Text] [Related]
19. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
Silva JM; Deuker MM; Baguley BC; McMahon M
Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
